Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 734749, 6 pages
Review Article

25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug

1Department of Neurology and Psychiatry, Sapienza University of Rome, 00185 Rome, Italy
2Department of Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire, AL10 9AB Hatfield, UK
3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy
4Department of Neuroscience and Imaging, University “G. D’Annunzio,” 66100 Chieti, Italy
5International Association for Applied Human Sciences (A.I.A.S.U.), 00100 Rome, Italy

Received 28 February 2014; Revised 6 June 2014; Accepted 6 June 2014; Published 3 July 2014

Academic Editor: Zsolt Demetrovics

Copyright © 2014 Francesco Saverio Bersani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Corazza, S. Assi, P. Simonato et al., “Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project,” Human Psychopharmacology, vol. 28, no. 4, pp. 317–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. F. S. Bersani, O. Corazza, P. Simonato et al., “Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy,” General Hospital Psychiatry, vol. 35, no. 5, pp. 571–573, 2013. View at Google Scholar
  3. F. Schifano, O. Corazza, A. Marchi et al., “Analysis of online reports on the potential misuse of benzidamine,” Rivista di Psichiatria, vol. 48, no. 3, pp. 182–186, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ninnemann and G. L. Stuart, “The NBOMe series: a novel, dangerous group of hallucinogenic drugs,” Journal of Studies on Alcohol and Drugs, vol. 74, no. 6, pp. 977–978, 2013. View at Google Scholar
  5. GPHIN, What is NBOME? Factivia, The Press, Christchurch, New Zealand, 2013.
  6. A. Shulgin and A. Shulgin, PIHKAL: A Chemical Love Story, Transform Press, Berkeley, Calif, USA, 1991.
  7. J. F. Casale and P. A. Hays, “Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3- and 4-methoxybenzyl analogues—part I,” Microgram Journal, vol. 9, no. 2, pp. 84–109, 2012. View at Google Scholar
  11. M. Keller, M. Blench, H. Tolentino et al., “Use of unstructured event-based reports for global infectious disease surveillance,” Emerging Infectious Diseases, vol. 15, no. 5, pp. 689–695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Ettrup, M. Hansen, M. A. Santini et al., “Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 4, pp. 681–693, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Zuba, K. Sekuła, and A. Buczek, “25C-NBOMe—new potent hallucinogenic substance identified on the drug market,” Forensic Science International, vol. 227, no. 1–3, pp. 7–14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Heim, Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-Methoxybenzyl partial structure [Ph.D. thesis], Free University, Berlin, Germany, 2003.
  18. M. R. Braden, J. C. Parrish, J. C. Naylor, and D. E. Nichols, “Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists,” Molecular Pharmacology, vol. 70, no. 6, pp. 1956–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Lawn, M. Barratt, M. Williams, A. Horne, and A. Winstock, “The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample,” Journal of Psychopharmacology, 2014. View at Publisher · View at Google Scholar
  21. World Health Orgainization, 36th ECDD Agenda Item 4.18, 25C-NBOMe, 2014.
  27. S. L. Hill, T. Doris, S. Gurung et al., “Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series,” Clinical Toxicology, vol. 51, no. 6, pp. 487–492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. H. Tang, C. K. Ching, M. S. Tsui, F. K. Chu, and T. W. Mak, “Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe,” Clinical Toxicology, vol. 52, no. 5, pp. 561–565, 2014. View at Publisher · View at Google Scholar
  29. S. Grautoff and J. Kähler, “Near fatal intoxication with the novel psychoactive substance 25C-NBOMe,” Medizinische Klinik, Intensivmedizin und Notfallmedizin, vol. 109, no. 4, pp. 271–275, 2014. View at Publisher · View at Google Scholar
  33. L. A. King, “New drugs coming our way—what are they and how do we detect them?” in Proceedings of the European Monitoring Centre for Drugs and Drug Addiction Conference (EMCDDA '09), Lisbon, Portugal, May 2009.
  35. “Temporary class drug order report on 5-6APB and NBOMe compounds,” UK Home Office, 2013.
  36. “NBOMe and Benzofury banned,” UK Home Office, 2013.
  37. Report of the International Narcotics Control Board for 2012, United Nations Publication.
  38. F. Schifano, A. Ricciardi, O. Corazza et al., “New drugs and role of web: the role of the Psychonaut Web Mapping Project,” Rivista di Psichiatria, vol. 45, no. 2, pp. 88–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Corazza, F. S. Bersani, R. Brunoro, G. Valeriani, G. Martinotti, and F. Schifano, “The diffusion of performance and image-enhancing drugs (PIEDs) on the Internet: the abuse of the cognitive enhancer piracetam,” Substance Use & Misuse, 2014. View at Publisher · View at Google Scholar
  40. A. Minichino, F. S. Bersani, W. K. Calò et al., “Smoking behaviour and mental health disorders—mutual influences and implications for therapy,” International Journal of Environmental Research and Public Health, vol. 10, pp. 4790–4811, 2013. View at Google Scholar
  41. EMCDDA-Europol 2012 Annual Report on the Implementation of Council Decision 2005/387/JHA: New Drugs in Europe, 2012.
  42. S. F. Butler, S. W. Venuti, C. Benoit, R. L. Beaulaurier, B. Houle, and N. Katz, “Internet surveillance: content analysis and monitoring of product-specific internet prescription opioid abuse-related postings,” The Clinical Journal of Pain, vol. 23, no. 7, pp. 619–628, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Schifano, O. Corazza, P. Deluca et al., “Psychoactive drug or mystical incense? Overview of the online available information on Spice products,” International Journal of Culture and Mental Health, vol. 2, no. 2, pp. 137–144, 2009. View at Google Scholar
  44. E. J. Cone, “Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet,” Drug and Alcohol Dependence, vol. 83, supplement 1, pp. S31–S39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. D. G. E. Caldicott, S. J. Bright, and M. J. Barratt, “NBOMe—a very different kettle of fish,” Medical Journal of Australia, vol. 199, no. 5, pp. 322–323, 2013. View at Google Scholar
  47. O. Corazza, F. Schifano, M. Farre et al., “Designer drugs on the Internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly,” Current Clinical Pharmacology, vol. 6, no. 2, pp. 125–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. R. J. Strassman, “Adverse reactions to psychedelic drugs. A review of the literature,” The Journal of Nervous and Mental Disease, vol. 172, no. 10, pp. 577–595, 1984. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Davey, F. Schifano, O. Corazza, and P. Deluca, “E-Psychonauts: conducting research in online drug forum communities,” Journal of Mental Health, vol. 21, no. 4, pp. 386–394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. O. Corazza, P. Simonato, J. Corkery, G. Trincas, and F. Schifano, ““Legal highs”: safe and legal “heavens”? A study on the diffusion, knowledge and risk awareness of novel psychoactive drugs among students in the UK,” Rivista di Psichiatria, vol. 49, no. 2, pp. 89–94, 2014. View at Google Scholar